Lipid dispersions and methods of use
AssigneeAlliance Pharmaceutical Corp.
InventorDavid M. Long, Jr.
Life of this patent
Estimating the term…
Abstract
Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.
Claims12
A fluorocarbon emulsion comprising an effective concentration of an agent that opposes the TAPR response selected from the group consisting of non-steroidal anti-inflammatory agents, anti-pyretic agents, and non-narcotic analagesic agents.
Dependencies are inferred from the claim text.